n(6)-carboxymethyllysine has been researched along with ramipril in 4 studies
| Studies (n(6)-carboxymethyllysine) | Trials (n(6)-carboxymethyllysine) | Recent Studies (post-2010) (n(6)-carboxymethyllysine) | Studies (ramipril) | Trials (ramipril) | Recent Studies (post-2010) (ramipril) |
|---|---|---|---|---|---|
| 803 | 44 | 365 | 2,151 | 606 | 509 |
| Protein | Taxonomy | n(6)-carboxymethyllysine (IC50) | ramipril (IC50) |
|---|---|---|---|
| Angiotensin-converting enzyme | Homo sapiens (human) | 0.004 | |
| Angiotensin-converting enzyme | Oryctolagus cuniculus (rabbit) | 0.253 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Blazícek, P; Dzúrik, R; Gazdíková, K; Heidland, A; Schinzel, R; Sebeková, K; Spustová, V; Syrová, D | 1 |
| Bassal, S; Cooper, ME; Deemer, ER; El-Osta, A; Forbes, JM; Jerums, G; Long, DM; Osicka, TM; Panagiotopoulos, S; Pete, J; Thallas-Bonke, V; Thomas, MC; Thorpe, SR | 1 |
| Baynes, JW; Bleich, M; Busch, AE; Deemer, EK; Dingermann, T; Huber, J; Münch, G; Schäfer, S; Schmid, K; Somoza, V; Wihler, C | 1 |
| Arnstein, M; Cooper, ME; Coughlan, MT; Forbes, JM; Gasser, A; Long, DM; Pete, J; Thallas-Bonke, V; Thorpe, SR; Tong, DC | 1 |
4 other study(ies) available for n(6)-carboxymethyllysine and ramipril
| Article | Year |
|---|---|
Effects of ramipril in nondiabetic nephropathy: improved parameters of oxidatives stress and potential modulation of advanced glycation end products.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Blood Glucose; Blood Pressure; Creatinine; Cystatin C; Cystatins; Diabetic Nephropathies; Female; Glomerulonephritis; Glycation End Products, Advanced; Homocysteine; Humans; Lipofuscin; Lysine; Male; Malondialdehyde; Middle Aged; Nephritis, Interstitial; Oxidative Stress; Polycystic Kidney Diseases; Ramipril; Severity of Illness Index; Statistics as Topic; Treatment Outcome | 2003 |
Modulation of soluble receptor for advanced glycation end products by angiotensin-converting enzyme-1 inhibition in diabetic nephropathy.
Topics: Alternative Splicing; Angiotensin-Converting Enzyme Inhibitors; Animals; Aorta; Arginine; Blotting, Western; Cattle; Cells, Cultured; Collagen; Diabetic Nephropathies; DNA Primers; Endothelium, Vascular; Glycation End Products, Advanced; Humans; Immunohistochemistry; Immunoprecipitation; Kidney Cortex; Lysine; Male; Microscopy, Fluorescence; Molecular Weight; Peptidyl-Dipeptidase A; Ramipril; Rats; Rats, Sprague-Dawley; Receptor for Advanced Glycation End Products; Receptors, Immunologic; Reverse Transcriptase Polymerase Chain Reaction; Skin; Time Factors; Up-Regulation | 2005 |
Renal accumulation and clearance of advanced glycation end-products in type 2 diabetic nephropathy: effect of angiotensin-converting enzyme and vasopeptidase inhibition.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Ascorbic Acid; Blood Glucose; Chromatography, High Pressure Liquid; Creatine; Deoxyglucose; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glycated Hemoglobin; Glycation End Products, Advanced; Heterocyclic Compounds, 3-Ring; Kidney; Lysine; Male; Oxidation-Reduction; Protease Inhibitors; Ramipril; Rats; Rats, Zucker; Spectrometry, Fluorescence | 2005 |
Combination therapy with the advanced glycation end product cross-link breaker, alagebrium, and angiotensin converting enzyme inhibitors in diabetes: synergy or redundancy?
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Cytosol; Diabetes Mellitus, Experimental; Drug Synergism; Drug Therapy, Combination; Enzyme Activation; Glycation End Products, Advanced; Kidney; Lysine; Male; Mitochondria; NF-kappa B; Oxidative Stress; Protein Kinase C; Ramipril; Rats; Rats, Sprague-Dawley; Receptor for Advanced Glycation End Products; Receptors, Immunologic; Renin-Angiotensin System; Superoxide Dismutase; Thiazoles; Vascular Endothelial Growth Factor A | 2007 |